We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
NEJM：口服 sunvozertinib 在 EGFR exon20ins 突变的 NSCLC 中将进展风险降低 35%。疗效、毒性和药物可用性的全面分析。了解更多。
